Ab1117 #ACR22 Deucravacitinib: TYK2 inhibitor in active SLE? 363 pt P2, double-blind PBO-controlled 48 wk study DEUC 3 mg BID, 6 BID, 12 QB vs PBO: At 32wk: DEUC 3BID & 6BID > PBO, sustained across all groups at 48wk. AEs: similar bw PBO and DEUC. No VTE @RheumNow #ACRBest https://t.co/uamJe05odq